Multidisciplinary Perspectives on the Cardiorenal Syndrome: Bridging the Gap between Cardiology and Nephrology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (15 January 2024) | Viewed by 3517

Special Issue Editor


E-Mail Website
Guest Editor
1. Service de Néphrologie, CHU de Strasbourg, Université de Strasbourg, Strasbourg, France
2. Team 3072 "Mitochondria, Oxidative Stress and Muscle Protection", Translational Medicine Federation of Strasbourg (FMTS), Faculty of Medicine, University of Strasbourg, Strasbourg, France
Interests: cardiorenal syndrome; cardiovascular disease; hemodialysis; critical care medicine; dialysis; chronic kidney failure; intensive care medicine; renal failure; kidney disease; chronic kidney disease; nephrology

Special Issue Information

Dear Colleagues,

Cardiorenal syndrome (CRS) is a complex interaction between the heart and kidneys, where dysfunction in one organ can cause or exacerbate dysfunction in the other. CRS is a significant clinical and public health issue, given the high prevalence of both cardiovascular and kidney disease; however, one of the major challenges in the diagnosis of CRS is the lack of objective criteria for the disease. Current classification systems do not fully account for the different stages and patterns of disease progression.

To better understand and diagnose CRS, new markers of acute and long-term risk for both organs are required. Diagnosis is currently based on clinical and laboratory findings, such as electrocardiograms as well as echocardiograms for the heart and blood as well as urine tests for the kidneys; however, these tests may be nonspecific and not distinguish between different types or stages of disease. Biological markers such as B-type natriuretic peptide and troponin have limited use in diagnosing CRS, and radiological tools such as MRI and CT scans are not routinely used due to their high cost and limited availability.

In conclusion, the diagnosis of cardiorenal syndrome remains a significant challenge due to the nonspecificity of clinical and laboratory findings. While traditional clinical and biological tools can provide valuable information, there is a need for more objective and accurate criteria for diagnoses.

Dr. Nans Florens
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiorenal syndrome
  • heart disease
  • kidney disease
  • diagnosis
  • classification
  • markers
  • electrocardiograms
  • echocardiograms
  • biological markers
  • radiological tools

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

3 pages, 184 KiB  
Editorial
Cardiorenal Syndrome: Ebony and Ivory
by Nans Florens
Diagnostics 2023, 13(9), 1539; https://doi.org/10.3390/diagnostics13091539 - 25 Apr 2023
Cited by 1 | Viewed by 1068
Abstract
The kidney and cardiovascular systems are closely interconnected and interact continuously in both physiological and pathological conditions [...] Full article

Review

Jump to: Editorial

16 pages, 999 KiB  
Review
Role of Semaphorin 3A in Kidney Development and Diseases
by Yizhen Sang, Kenji Tsuji, Hiroyuki Nakanoh, Kazuhiko Fukushima, Shinji Kitamura and Jun Wada
Diagnostics 2023, 13(19), 3038; https://doi.org/10.3390/diagnostics13193038 - 25 Sep 2023
Cited by 2 | Viewed by 1763
Abstract
Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus [...] Read more.
Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence has revealed that excess SEMA3A expression and the subsequent signaling pathway aggravate kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports have demonstrated that the inhibition of SEMA3A ameliorated kidney injury via a reduction in cell apoptosis, fibrosis and inflammation; thus, SEMA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized the current knowledge regarding the role of SEMA3A in kidney pathophysiology and their potential use in kidney diseases. Full article
Show Figures

Figure 1

Back to TopTop